Related references
Note: Only part of the references are listed.Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies
Ying C. Ou et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.
Constantine Si Lun Tam et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial
Gang An et al.
BLOOD (2020)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Waldenstrom macroglobulinemia: 2019 update on diagnosis, risk stratification, and management
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
Chloe Pek Sang Tang et al.
LEUKEMIA & LYMPHOMA (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia
Zachary R. Hunter et al.
BLOOD ADVANCES (2018)
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2017)
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang et al.
BLOOD (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenstrom macroglobulinaemia cells
Yang Cao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia
Y. Cao et al.
LEUKEMIA (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
Aldo M. Roccaro et al.
BLOOD (2014)
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Meletios A. Dimopoulos et al.
BLOOD (2014)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Kenneth C. Anderson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
Share Paper
